Angststörungen
Studienlage · Detail Systematic Review · Angststörungen · 2020

Use of cannabidiol in anxiety and anxiety-related disorders

Gemischt GRADE Hoch 135 Zitate
Stichprobek = 8 Studien
Dauerdatabase inception through June…
KontrolleVariiert je Studie
EndpunktAngstskalen
Verblindungn.a.
DesignSystematic Review
Cannabinoidcbd
Max. Dosis400.0 mg
Applikationoral
Kernaussage

CBD zeigte verbesserte klinische Ergebnisse in mehreren Angststörungen, war gut verträglich mit minimalen Nebenwirkungen, aber Evidenz ist begrenzt und heterogen.

Zusammenfassung

Systematische Review zu CBD bei Angststörungen; k=8 Studien (6 kleine RCTs, 1 Fallserie, 1 Fallbericht). Dosis-Range 6-400 mg CBD oral/sublingual. CBD zeigte Verbesserung auf verschiedenen Angst-Assessment-Skalen bei gesunden Probanden, generalisierter Angststörung, sozialer Phobie und PTBS-Angst-Komponente. Gut verträglich, minimale Nebenwirkungen. Keine Studien zu Panikstörung, spezifischer Phobie, Trennungsangst oder Zwangsstörung identifiziert.

P
PopulationErwachsene mit Angststörungen (u.a. generalisierte Angststörung, soziale Angststörung, PTSD-Angstkomponente) sowie gesunde Probanden – gepoolte Patientenzahl nicht berichtet
I
InterventionCannabidiol (CBD), oral als Kapsel oder sublinguales Spray, Dosen 6–400 mg, als Mono- oder Kombinationstherapie
C
KontrolleVariiert je Studie (Placebo in RCTs)
O
OutcomeCBD zeigte in allen eingeschlossenen Studien verbesserte klinische Ergebnisse auf verschiedenen Angstskalen; gut verträglich mit minimalen Nebenwirkungen (v.a. Fatigue und Sedierung)
Vertrauen in die Evidenz
Hoch

Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.

Qualitätsprofil
Größe
Verblindung
Effektstärke Gemischt
Zitate / Jahr
Autoren
Skelley J W, Deas C M, Curren Z et al.
DOI 10.1016/j.japh.2019.11.008
Design: Systematic Review
Teilen
Abstract
Objective: Cannabidiol (CBD) has a proposed novel role in the management of anxiety owing to its actions on the endocannabinoid system. The purpose of this systematic review was to evaluate the current evidence on the safety and efficacy of CBD in anxiety and anxiety-related disorders. Data Sources: A literature search was conducted on PubMed, Google Scholar, and International Pharmaceutical Abstracts from database inception through June 2019. A bibliographic search of relevant articles was also conducted. Study Selection: Articles published from case reports, case series, or randomized controlled trials on human subjects were included in the review if they examined the safety and efficacy of CBD therapy in anxiety and anxiety-related disorders. Data Extraction: Two reviewers independently extracted the following data from the articles: year of publication; study design; patient characteristics (sex; type of anxiety disorder; use of concomitant anxiolytic therapy); dosing strategy and route of CBD administration; and safety and efficacy outcomes. Results: Eight articles were included in the review: 6 small, randomized controlled trials; 1 case series; and 1 case report. These studies examined the role of CBD in the anxiety response of healthy volunteers; in generalized anxiety disorder; in social anxiety disorder; and in the anxiety component of posttraumatic stress syndrome. No articles that evaluated CBD in panic disorder, specific phobia, separation anxiety, and obsessive-compulsive disorder were identified. In the studies, CBD was administered orally as a capsule or as a sublingual spray and as either monotherapy or adjunctive therapy. Doses varied widely, with studies employing fixed CBD doses ranging from 6 mg to 400 mg per dose. Various anxiety assessment scales were used in the studies to assess efficacy, with CBD demonstrating improved clinical outcomes among the instruments. In general, CBD was well-tolerated and associated with minimal adverse effects, with the most commonly noted adverse effects being fatigue and sedation. Conclusion: CBD has a promising role as alternative therapy in the management of anxiety disorders. However, more studies with standardized approaches to dosing and clinical outcome measurements are needed to determine the appropriate dosing strategy for CBD and its place in therapy.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel